Loading
A phase 1/2 trial of tislelizumab, bevacizumab and capecitabine in triple-negative breast cancer, run by National University Hospital, Singapore, not yet recruiting.
Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease is a phase 1/2, interventional study registered as NCT07681297 by National University Hospital, Singapore, with a registry enrolment figure of 154 participants, started 2026-08 and due to reach its primary completion in 2028-08. Interventions recorded: Tislelizumab + Bevacizumab + Capecitabine. Conditions listed: Advanced Solid Tumor Cancer; Triple-Negative Breast Cancer (TNBC); CNS Disease; Breast Cancer. Triple-negative eligibility wording from the registry: "TNBC Cohort Inclusion Criteria". Sites: Singapore. No results are recorded here; the registry entry is the source.
Shares Tislelizumab, Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Tislelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Bevacizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Bevacizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag tnbc-deep-dive.